Home » Thought Leadership » Page 6

Thought Leadership

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 104 posts
RESUBMISSIONS WITH RWE CAN THEY HELP CHANGE YOUR BENEFIT RATING
May 18, 2020 | Research posters

ISPOR Annual 2020: Re-Submissions with RWE: Can They Help Change Your Benefit Rating?

A research poster that aims to understand the role of RWE in re-submissions and determine if this type of evidence can help to improve HTA outcomes when products are re-assessed by the Haute Autorité de Santé (HAS) in France and Gemeinsamer Bundesausschuss (G-BA) in Germany.

THE RESULTANT IMPACT OF HEOR DATA ON US PAYER FORMULARY COVERAGE WEB
May 18, 2020 | Research posters

ISPOR Annual 2020: The Resultant Impact of HEOR Data on US Payer Formulary Coverage

A research poster identifying instances where manufacturer HEOR data and/or pharmacoeconomic models either influenced positive changes, or had limited tangible impact on resultant US payer coverage decisions.

Speaking of Access: The Management of Tumor-Agnostic Therapies from CBPartners
May 13, 2020 | Podcasts

Speaking of Access: The Management of Gene Therapies (Now and in the Future)

Andrew Gould asks our US payer panel for their expert perspectives surrounding the management of gene therapies, both now and in the future.

CBPartners' Pharma Take-Away: AMARIN's VASCEPA patent loss: is it obvious(ness)?
May 7, 2020 | Podcasts

CBPartners’ Pharma Take-Away: AMARIN’s VASCEPA patent loss: is it obvious(ness)?

Patent management is the hot topic of this episode. The focus is on AMARIN’s leading product, VASCEPA, a drug made up of natural derivatives such as fish oil and was approved by the FDA in December 2019.

Speaking of Access: The Management of Tumor-Agnostic Therapies from CBPartners
May 5, 2020 | Podcasts

Speaking of Access: Pricing for Uncertain Indications

Andrew Gould asks our US payer panel for their expert perspectives surrounding pricing for uncertain future indications.